 
UVA CENTER FOR DIABE TES TECHNOLOGY  
 
 
Fully Automated Closed Loop Control in 
Adolescents with Type 1 Diabetes (RocketAP)  
 
 
 
 Protocol Chair  
Mark DeBoer, MD  
University of Virginia  
Center for Diabetes Technology  
 
 
Version Number: v1. 3 
 17-Nov-2020  
  
CLINICAL PROTOCOL     
 
 
 
RocketAP _17-Nov-2020   Page 2 of 61 
 
KEY ROLES  
 
Protocol Principal Investigator   
Name, degree Mark DeBoer, MD, MSc., MCR  
Institution Name  University of Virginia Center for Diabetes Technology  
  
CLINICAL PROTOCOL     
 
 
 
RocketAP _17-Nov-2020   Page 3 of 61 
 
PROTOCOL VERSION HISTORY 
Version 
Number  Author(s)  Approver  Effective Date Revision Description  
1.0 Mark DeBoer    Original Protocol  
1.1 Jon Olson  Mary Oliveri  10-Aug-2020  FDA Review:  
• Added stopping criteria of either 
one attributable DKA event or 
one attributable severe 
hypoglycemia event  (section 
11.9.1) 
• Added Definition of Data Breach 
(section 11.11 ) 
1.2 Jon Olson  Mark DeBoer  21-Oct-2020  IRB FB Review:  
• Inserted Covid -19 Precautions 
(section 10.3 ) 
1.3 Jon Olson  Mark DeBoer  11-Nov-2020  Follow -up Review:  
• Expanded on Covid -19 precautions  
  
CLINICAL PROTOCOL     
 
 
 
RocketAP _17-Nov-2020   Page 4 of 61 
 
SITE PRINCIPAL INVES TIGATOR STATEMENT OF  COMPLIANCE  
 
Protocol Title: Fully Automated Closed Loop Control in Adolescents with Type 1 Diabetes 
(RocketAP) 
Protocol Version/Date: v1. 2/17-Nov-2020  
I have read the protocol specified above.  In my formal capacity as a Site Principal Investigator, 
my duties include ensuring the safety of the study participants enrolled under my supervision.  It is understood that all information pertaining to the study will be held strictly confidential and 
that this confidentiality requirement applies to all study staff at this site.  
This trial will be carried out in accordance with ICH E6 Good Clinical Practice (GCP) and as required 
by the following: United States (US) Code of Federal Regulations (CFR) applicable to clinic al 
studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812).  
As the Principal Investigator, I will assure that no deviation from, or changes to the protocol will take place without prior agreement from the sponsor and documented approval from the 
Institutional Review Board (IRB), or other approved Ethics Committee, except where necessary to eliminate an immediate hazard(s) to the trial participants.  
All key personnel (all individuals responsible for the design and conduct of this trial) have completed Human Participants Protection Training and Good Clinical Practice Training.  Further, I agree to ensure that all staff members involved in the conduct of this study are informed about 
their obligations in meeting the abo ve commitments.  
 
Investigator’s Signature __________________________________ Date: _____ / _____ / _____   
Investigator’s Name: ________________________________  
Site Name:  University of Virginia  
  
CLINICAL PROTOCOL     
 
 
 
RocketAP _17-Nov-2020   Page 5 of 61 
 
LIST OF ABBREVIATIONS 
ABBREVIATION  DEFINITION  
ADRR  Average Daily Risk Range  
AP Artificial Pancreas  
BG Blood Glucose  
BT/BTLE  Bluetooth, Bluetooth low energy  
CGM Continuous Glucose Monitoring  
CLC Closed -Loop Control  
CiQ Tandem t:slim X2 Insulin Pump with Control- IQ Technology  
CSII Continuous Subcutaneous Insulin Injection  
DKA Diabetic Ketoacidosis  
DSMB  Data Safety Monitoring Board  
FDA Food and Drug Administration  
GCP Good Clinical Practice  
HbA1c  Hemoglobin A1c  
HBGI  High Blood Glucose Index  
IDE Investigational Device Exemption  
IOB Insulin-on -Board  
LBGI  Low Blood Glucose Index  
POC Point -of-Care 
QC Quality Control  
rMPC  Regular Model Predictive Control  
UI User Interface  
  
CLINICAL PROTOCOL     
 
 
 
RocketAP _17-Nov-2020   Page 6 of 61 
 
PROTOCOL SUMMARY  
PARTICIPANT AREA  DESCRIPTION  
Title  Fully Automated Closed Loop Control in Adolescents with Type 1 Diabetes (RocketAP)  
Investigational Device  Reactive Open -loop and Carbohydrate Kinetics EsTimation (Rocket) based Fully Automated 
Artificial Pancreas  
Objectives  The purpose of this study is to show the safety and feasibility of a fully new fully automated 
AP controller based on automated meal priming and CHO kinetics estimation, within the 
UVA AP modular architecture.  
Study Design  A randomized cross -over trial assessing glycemic responses to two different approaches to 
insulin dosing for carbohydrate ingestion (announced vs. unannounced), with two different 
AP systems (Rocket AP vs. USS Virginia, aka Control -IQ, in random order)  
Number of Sites  One 
Endpoint  The primary outcome will be time in range 70 -180 mg/dL from dinner time until midnight.  
Population  Key Inclusion Criteria  
• Age 1 2-25 
• Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year  
• Currently using insulin for at least six months  
• Currently using insulin pump for at least three months  
Key Exclusion Criteria  
• Hemoglobin A1c < 12%  
Sample Size   • Pilot Study: complete up to 3 participant s  
• Main Study: complete up to 20 participants  
Treatment Groups  • Rocket AP 
• USS Virginia, aka Control- IQ  
Participant Duration  Pilot Stud y:  Participants will be admitted to a local hotel for approximately 4 2 hours and will 
have an experimental dinner with the Rocket AP with no -carbohydrate announcement.    
Main Study: Participants will be admitted to a local hotel for approximately 64  hours .  
Protocol Overview/Synopsis  Participants  will be randomized to either the Rocket AP experimental group  or the Control-IQ 
control group . Each group will participate in two (2) ~ 64 ho ur admissions. During one 
admission, the Rocket AP (Meal Control Module) group will have one dinner session with a 
normal carbohydrate announcement and one dinner session with no carbohydrate announcement.  During the alternate  admission, the participate will have the will have one 
dinner session with a normal carbohydrate announcement and one dinner session with no 
carbohydrate announcement while using the Control -IQ equipment.  These studies will be 
performed under precautiona ry conditions where we will attempt to create a COVID- free 
“bubble” where participants and study personnel will have two rounds of testing to ensure that those in the “bubble” have very low risk of infection.  
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 7 of 61 
 STUDY VISITS AND PROCEDURES SCHEDULE   
 
Screening  Study 
Equipment 
Training  CGM Run -In 
Phase   Pre-
Admission 
Check -In  Study 
Admission 
#1 Post -
Admission 
Check -In Pre-
Admission 
Check -In Study 
Admission 
#2 Post -
Admission 
Check -In 
Location  Clinic /   
Remote   Clinic /   
Remote 
Clinic / 
Remote  Home  Phone/  
Email/Text    
Hotel Phone/  
Email/Text   Phone/  
Email/Text    
Hotel Phone/  
Email/Text   
Visit  1 2 x 3 4 5 6 7 8 
Hotel Day  NA NA x NA 1-4 NA NA 5-8 NA 
Informed 
Consent  X         
Eligibility 
Assessment  X         
Medical History  X         
HbA1c  X         
Pregnancy test 
(if applicable ) X X   X   X  
Physical Exam  X         
Vital Sig ns 
(height/weight)  X         
Randomization      X     
COVID Testing     X X   X  
CGM Run -In 
(non -G6 users)    ~14 days if 
needed        
Study Dinner 
Sessions      Day 2 & 3   Day 6 & 7  
Survey / 
Questionnaires   X   Post    Post  X 
Review diabetes 
management 
and AEs      X  
X  X X 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 8 of 61 
  
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 9 of 61 
 Table of Contents  1 
Chapter 1 Background  ......................................................................................................... 13 2 
1.1 Introduction  ........................................................................................................................ 13 3 
1.2 Study Objective  ................................................................................................................... 13 4 
1.3 Study Design ........................................................................................................................ 14 5 
1.4 Study Device Download  ...................................................................................................... 17 6 
1.5 Study System Issues  ............................................................................................................ 17 7 
1.6 Purpose/Objectives of Clinical Study  .................................................................................. 17 8 
Chapter 2 Study Devices  ...................................................................................................... 18 9 
2.1 Insulin Pump  ....................................................................................................................... 18 10 
2.2 Continuous Glucose Monitor  .............................................................................................. 18 11 
2.3 Blood Glucose Meter and Strips  ......................................................................................... 18 12 
2.4 Ketone Meter and Strips  ..................................................................................................... 18 13 
2.5 Study Devices Accountability Procedures ........................................................................... 18 14 
Chapter 3 Study Screening  ................................................................................................... 19 15 
3.1 Participant Recruitment and Enrollment  ............................................................................ 19 16 
3.2 Informed Consent and Authorization Procedures  .............................................................. 19 17 
3.3 Screening Procedures  ......................................................................................................... 19 18 
3.4 Participant Inclusion Criteria ............................................................................................... 19 19 
3.5 Participant Exclusion Criteria  .............................................................................................. 20 20 
3.6 Eligibility Screening Procedures  ......................................................................................... 21 21 
3.7 Demographic Data Survey  .................................................................................................. 22 22 
Chapter 4 Randomization .................................................................................................... 23 23 
4.1 Pilot Study Participants  ....................................................................................................... 23 24 
4.2 Main Study Participants  ...................................................................................................... 23 25 
Chapte r 5 Study Equipment Training  .................................................................................... 24 26 
5.1 CGM Training  ...................................................................................................................... 24 27 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 10 of 61 
 5.2 Activity Tracker  ................................................................................................................... 25 28 
5.3 Study Insulin Pump  ............................................................................................................. 25 29 
Chapter 6 Pilot Study  ........................................................................................................... 27 30 
6.1 Run -In Phase  ....................................................................................................................... 27 31 
6.2 Qualifications and Role of the Staff  .................................................................................... 27 32 
6.3 Pre -Admission Check -In Visit  .............................................................................................. 27 33 
6.4 Admission Check -In ............................................................................................................. 28 34 
6.5 Hotel Admission Glycemic Treatment Guidelines  .............................................................. 28 35 
6.6 Study Meals  ......................................................................................................................... 29 36 
6.7 Admission Activities  ............................................................................................................ 29 37 
6.8 Admission Discharge  ........................................................................................................... 29 38 
6.9 Post A dmission Check -In Visit  ............................................................................................. 29 39 
6.10 Medical Monitor Review  ................................................................................................... 30 40 
Chapter 7 Main Study  .......................................................................................................... 31 41 
7.1 Run -In Phase  ....................................................................................................................... 31 42 
7.2 Qualificatio ns and Role of the Staff  .................................................................................... 31 43 
7.3 Pre -Admission Check -In Visit  .............................................................................................. 31 44 
7.4 Admission Check -In ............................................................................................................. 32 45 
7.5 Hotel Admission Glycemic Treatment Guidelines  .............................................................. 32 46 
7.6 Study Meals  ......................................................................................................................... 33 47 
7.7 Admission Activities  ............................................................................................................ 33 48 
7.8 Admission Discharge  ........................................................................................................... 34 49 
7.9 Post Admission Questionnaire  ............................................................................................ 34 50 
7.10 Post Admission Check -In Visit  ........................................................................................... 34 51 
7.11 Medical Monitor Review  ................................................................................................... 34 52 
Chapter 8 Medical Monitor Review  ...................................................................................... 35 53 
8.1 Medical Monitor Study Safety Data Review  ....................................................................... 35 54 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 11 of 61 
 8.2 Medical Monitor Decisions  ................................................................................................. 35 55 
8.3 Medical Monitor Main Study Safety Data Review  .............................................................. 35 56 
Chapter 9 Testing Procedures  .............................................................................................. 36 57 
9.1 Laboratory / Point of Care Testing  ...................................................................................... 36 58 
9.2 Questionnaire Schedule  ...................................................................................................... 36 59 
Chapter 10 Risks Associated with Clinical Trial  ..................................................................... 37 60 
10.1 Potential Risks and Benefits of the Investigational Device  ............................................... 37 61 
10.2 General Considerations ..................................................................................................... 41 62 
10.3 COVID 19 Risk Mitigation Plan and Justification  ............................................................... 41 63 
Chapter 11 Adverse Events, Device Issues, and Stopping Rules  ............................................. 45 64 
11.1 Definitions  ......................................................................................................................... 45 65 
11.2 Reportable Events  ............................................................................................................. 46 66 
11.3 Relationship of Adverse Event to Study Device  ................................................................ 47 67 
11.4 COVID Transmission  .......................................................................................................... 48 68 
11.5 Inten sity of Adverse Event  ................................................................................................ 48 69 
11.6 Coding of Adverse Events  ................................................................................................. 49 70 
11.7 Outcome of Adverse Events  ............................................................................................. 49 71 
11.8 Reportable Device Issues  .................................................................................................. 50 72 
11.9 Timing of Event Reporting  ................................................................................................ 51 73 
11.10 Stopping Criteria  ............................................................................................................. 51 74 
11.11 Independent Safety Oversight  ........................................................................................ 52 75 
11.12 Definition  of a Data Breach  ............................................................................................. 52 76 
Chapter 12 Miscellaneous Considerations  ............................................................................ 53 77 
12.1 Prohibited Medications, Treatments, and Procedures  .................................................... 53 78 
12.2 Participant Withdrawal ..................................................................................................... 53 79 
12.3 Confidentiality  ................................................................................................................... 53 80 
Chapter 13 Statistical Consideration  .................................................................................... 54 81 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 12 of 61 
 13.1 Design and Randomization  ............................................................................................... 54 82 
13.2 Sample Size  ....................................................................................................................... 54 83 
13.3 Outcome Measures  ........................................................................................................... 54 84 
13.4 Safety Analyses  ................................................................................................................. 55 85 
13.5 Baselin e Descriptive Statistics  ........................................................................................... 56 86 
13.6 Device Issues  ..................................................................................................................... 56 87 
Chapter 14 Data Collection and Monitoring  ......................................................................... 58 88 
14.1 Case Report Forms and Device Data  ................................................................................. 58 89 
14.2 Study Records Retention  .................................................................................................. 58 90 
14.3 Protocol Deviations  ........................................................................................................... 58 91 
Chapter 15 Ethics/Protection of Human Participants  ............................................................ 59 92 
15.1 Ethics Standard  ................................................................................................................. 59 93 
15.2 Institu tional Review Boards  .............................................................................................. 59 94 
15.3 Informed Consent Process  ................................................................................................ 59 95 
Chapter 16 References  ......................................................................................................... 61 96 
  97 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 13 of 61 
 Chapter 1   Background  98 
 
 99 
Maintaining blood glucose (BG) control among adolescents with Type 1 diabetes (T1D) is arguably 100 
the greatest challenge in entire field of T1D.  While the reasons for this poor control are varied, 101 
a significant issue relates to missed meal boluses, which affects 65% of adolescents at least once 102 
weekly,1 with 38% missing at least 15% of their boluses.2 Adolescents who miss four boluses 103 
weekly  experience an increase of 1% in their HbA1c.1  While the advent of the artificial pancreas 104 
(AP) in this age range offers promise of safe reductions in HbA1c,3 we previously found that the 105 
AP onl y partly compensates for missed prandial insulin4—demonstrating that some form of meal 106 
announcement is necessary for good BG control, even with an AP.  One way to automate this 107 
process is by sharing the prandial dosing responsibilities  between an automated insulin priming 108 
(based on CGM condition predictive of a safe situation for such insulin dosing) and a closed loop 109 
controller capable of reconstructing (estimating) the prevailing glucose rate of appearance from 110 
an unannounced meal. We have developed such an insulin priming schema and integrated it into 111 
a new version of the robust Model Predictive Controller UVa AP system  (called the Rocket AP).     112 
In the current study, we are testing this new AP system in two configurations : hybrid and fully 113 
automated,  among up to 2 0 adolescents . Our primary outcome will be one of efficacy in assessing 114 
how well the new system controls post- prandial blood sugar in the absence of carbohydrate 115 
announcement as compare d to the same situation but using  the Control -IQ closed loop 116 
algorithm, also designed at UV a and using the same modular architecture and safety system, but 117 
without insulin priming and with a  less advanced model -based controller .  Further comparisons 118 
will be made to blood sugar control on Rocket AP with carbohydrate announcement and on 119 
Control -IQ with carbohydrate announcement.  Adolescents will be started on the respective UVa 120 
artificial pancreas system s (Rocket AP and Control -IQ in random order, both implemented  on the 121 
DiAs  platform, MAF 2109 ) and followed over the course of two dinners on each of the two 122 
platforms: a dinner where carbohydrate is announced as normal and the second where no 123 
anno uncement is made.    124 
We hypothesize that performances of  Rocket AP in fully automated mode will lie in  between 125 
Hybrid and Fully  Automated Control -IQ. In time, this may provide an opportunity to improve 126 
blood sugar control among adolescents who miss meal ann ouncement.  127 
 
 128 
The purpose of this study is to  test the Rocket AP closed loop algorithm, a new algorithm 129 
leveraging the UVA modular architecture  to insert a new basal rate modulator and a new  insulin 130 
priming  schema inside our validated framework including the UVA safety system module . We will 131 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 14 of 61 
 enroll up to 2 0 adolescents in a randomized cross -over trial, comparing blood glucose time in 132 
range 70 -180 mg/dL following dinners consumed with or without announcement contrasting our 133 
currently approved algorithm (Control- IQ) with this new version .  134 
 
 135 
We will recruit  approximately  30 participants,  age 12 -25 years , with a goal to have up to 20 136 
participants complete the trial. The study will be performed overnig ht at a local hotel  near the 137 
University Medical Center.   This will be done under conditions where we will attempt to create 138 
a COVID -free “bubble,” further described in section 10.3.    The pilot study, which will have 139 
between 1 and 3 participants and be up to 2 days will be in a hotel/rented house . (Use of a rented 140 
house for a small group allows for more control over contact with non -study individuals. )  141 
Additional COVID- 19 precautions are described  below still apply.  142 
 Recruitment and S creening  143 
Participants  will be recruited from the UVa Center for Diabetes Technology registry, social media 144 
advertisements, physician contacts at pediatric diabetes clinics in Virginia (UVa, Virginia 145 
Commonwealth University, Children’s Hospital of the King’s Daughters) and camp  attendance 146 
data.  Potential participants will be informed of the study and offered a chance to have answered 147 
questions.  Participants , and a parent  if <18 years old,  will provide written informed consent and, 148 
if participant is < 18 years old , assent  will also be obtained .  Participants will be screened at a visit 149 
before the beginning of hotel stay to confirm eligibility.  The scre ening visit can be performed by  150 
video conferencing.   Prior to participation  in the hotel study , participants will agree to  self-isolate 151 
and have COVID testing.  152 
 CGM Data Collection  153 
Following enrollment participants will be trained in use of the Dexcom G6 system, provided with 154 
adequate study supplies and have a Dexcom sensor placed .  This training can also be done via 155 
video con ferencing, with supplies sent to the family.  This study visit will be followed by 2 weeks 156 
of CGM and pump data collection at the participant’s home/usual routine.  Participants who have 157 
previously used a Dexcom CGM and have glucose data for the 2 weeks pr ior to the screening visit 158 
can skip the 2 -week data collection.   Participants will then be randomized to be on one artificial 159 
pancreas system or the other 1st (RocketAP or Control -IQ).  This will be performed using two 160 
permuted blocks of 4 and one permute d block of 2.  161 
 Study Hardware/Software  162 
The study itself will involve use of the DiAs prototyping platform (MAF 2109), connected to a 163 
Tandem t:ap research pump and a Dexcom G6 sensor, and implementing either  Rocket AP or 164 
Control -IQ (in random order) .  Upon ar rival at the  hotel, participants will be instructed in how to 165 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 15 of 61 
 use the Tandem research pump as well as the UVa AP  system s, including stopping the system 166 
and bolusing for food.  167 
 Timing of UVa Artificial Pancreas Use  168 
Upon arrival  to  hotel , participants will be connected to a Tandem research pump  connected to 169 
the UVa DiAs platform and their Dexcom G6 Transmitter will be linked with DiAs. Participants will 170 
then be taught how to use DiAs in this configuration. The research pump will be progra mmed  171 
with the adolescent’s usual insulin parameters.     172 
Participants will have their blood sugar managed through this system during the entirety of the 173 
time at  hotel .   174 
 Study Dinner Ses sions  175 
Study dinners and timing:  On four  separate days  (hotel  days 2, 3, 6 and 7 ), participants will be 176 
followed for th e experimental dinners  as part of the Study Dinner Sessions to compare blood 177 
glucose contro l using four  different approaches to insulin management for carbohydrate control  178 
(Figure 1).  These Study Dinner Sessions start approximately 3 -4 hours before the dinner and 179 
continue for approximately 12 hours after the dinner .  During the Study Dinner Sessions, 180 
participants will consume structured dinners  (with identical protein, fat, and carbohydrate 181 
content between the Study Dinner Sessions ) while on the two UVa AP closed loop alg orithms 182 
(Rocket AP or Control -IQ—in random order); for each , insulin dosing  on the first Study Dinner 183 
Session will be via normal carbohydrate announcement and  the DiAs CGM -based bolus 184 
calculator, and  on the second Study Dinner Session with no carbohydrate a nnouncement (In the 185 
case of the Rocket AP artificial pancreas system, the insulin priming  will be in place to detect and 186 
dose for unannounced carbohydrate.)  For other meals on the artificial pancreas system during 187 
the  hotel stay , normal carbohydrate annou ncement will be performed.  188 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 16 of 61 
  189 
Figure 1:  Timeline of the Study Dinner Sessions  190 
The order of the AP system tested (Rocket AP vs. Control -IQ) is determined randomly.  The order 191 
of carbohydrate (CHO) announcement will be the same in both cases.  Study Dinner Sessions  will 192 
likely be performed during two   hotel admissions  separated by no more than 8 weeks . 193 
Blood glucose levels will  be followed via  continuous glucose monitor, and the primary outcome 194 
will be percent time in blood glucose range 70 -180 mg/dL during the 6  hours following start of 195 
the meal . Study staff who will be present will include nursing staff and technical staff; a study 196 
physician will be available either on -site or nearby off- site at all times . Hyperglycemia and 197 
hypoglycemia treatment protocols will be followed per CDT protocol. We anticipate more 198 
significant cases of hyperglycemia during dinners managed without car bohydrate 199 
announcement ; participants will be encouraged to drink large amounts of non- caloric beverages, 200 
particularly after these meals .    201 
The UVa AP  system s will be  initiated  upon arrival to the hotel the afternoon/evening before the 202 
first of the Study Dinner Sessions . UVa CDT study staff will monitor CGM output continuously and 203 
manage blood sugar control issues.  At the end of the second Study Dinner Session , the 204 
participant will be placed on home insulin management (or adjustment based on diabetes camp  205 
management) .  206 
Stopping criteria for and individual study dinner session:  A Study Dinner Session will be stopped 207 
for an individual participant for any of the following:  208 
• Ketones >1.5 mmol  209 
• Known site failure   210 

CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 17 of 61 
 • Two separate hypoglycemia events where the blood glucose falls below 50  mg/dL  211 
• The behavior of the participant is such that there is concern about his/her ability to 212 
continue to adhere to the protocol  213 
• At the discretion of the study physician.  214 
 
 215 
Before discharge from the hotel, all stu dy devices will be turned in to study staff for device 216 
download  and the participants will be placed on usual diabetes management. 217 
 
 218 
If the CGM signal becomes unavailable for more than 20 minutes consecutively, closed loop will 219 
not operate  to automatically adjust insulin.  If the CGM is not connected, the system will revert 220 
to usual function of the pump and deliver insulin with the insulin dosing parameters programmed 221 
in the system for that individual. Resumption of c losed -Loop will occur  automatically once CGM 222 
signal is available again.  223 
If the study system is unable to maintain pump connectivity , the pump will automatically revert 224 
to pre -programmed basal insulin delivery after 30minutes without any need for instruction from 225 
the user.  226 
 
 227 
 Study Participants  228 
Enrollment in the Pilot Study will proceed with the goal of completing 3 participant s. Up to 6 229 
participants may sign the consent/assent forms.   230 
Enrollment in th e Main Study will proceed with the goal of completing approximately 20 231 
participants .  Up to 30 participants may sign the Main Study consent /assent  forms .  232 
 Clinical Sites  233 
The study will be performed at the University of Virginia, with screening procedures taking pl ace 234 
at the Clinical Research Unit or at a local hotel/rental house.   235 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 18 of 61 
 Chapter 2  Study Devices 236 
 
 237 
The study system s will utilize  the Tandem t:ap research pump  connected to the UVa DiAs system 238 
run on a dedicated external smart phone , running either the RocketAP control algorithm or the 239 
Control -IQ control algorithm (in random order).   240 
 
 241 
The study CGM will include Dexcom G6 transmitter and sensors. The CGM sensor is viable for 10 242 
days.  243 
 
 244 
Blood glucose le vels will be measured using the Accu -Chek Guide blood glucose meter 245 
(glucometer). The CGM device will be calibrated, if needed, using the study glucometer and strips 246 
in accordance with the manufacturer’s labeling.  247 
 
 248 
Blood ketone leve ls will be measured using the Abbott Precision Xtra meters and strips in 249 
accordance with the manufacturer’s labeling. The blood glucose meter component of the 250 
Precision Xtra Device will not be used.  The ketone meter will be available for staff use during the 251 
study admissions.  252 
 
 253 
Device serial numbers will be recorded and use of equipment will be tracked.   254 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 19 of 61 
 Chapter 3  Study Screening   255 
 
 256 
Pilot Study:  Enrollment goal in the Pilot Study will be to complete 1 participant.  Up to 4 257 
participants may sign consent/assent forms.  258 
Main Study:  Enrollment in the s tudy will proceed with the goal of completing up to 20 259 
participants .  Participants will initially be randomized for the order of their 3 experimental meals 260 
use during the study.  Up to 30  participants may sign the consent/assent forms.  261 
 
 262 
Before consent has been obtained, participants will be asked  inclusion/ exclusion criteria 263 
questions during pre -screening  to determine study eligibility. Before completing any procedures 264 
or collecting any data that are not part of usual care, written informed consent (and assent, when 265 
applicable) will be obtained. P otential eligibility may be assessed as part of a routine -care 266 
examination.   267 
A participant is considered enrolled when the informed consent form has been signed by the 268 
participant and the study team . 269 
Consenting procedures and documentation is defined in s ection 15.3 .  270 
 
 271 
After informed consent has been signed, a potential participant will be evaluated for study 272 
eligibility through the elicitation of a medical history, performance of a physical examination 273 
by licensed  personnel , and pregnancy testing (if applicable) to screen for exclusionary medical 274 
conditions.   A physical exam documented in the prior year can suffice for the physical exam. 275 
Individuals who do not initially meet study eligibility requirements may be rescreened at a later 276 
date per investigator discretion.  277 
 
 278 
The participants must meet all of the following inclusion criteria in order to be eligible to 279 
participate in the study.  280 
1. Age ≥12 .0 and ≤ 25 year s old  at time of consent  281 
2. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year  282 
3. Currently using insulin for at least six months  283 
4. Currently using insulin pump for at least three months   284 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 20 of 61 
 5. Using insulin parameters such as carbohydrate ratio and correction factors consistently on 285 
their pump in order to dose insulin for meals or corrections  286 
6. Access to internet and willingness to upload data during the study as needed  287 
7. For females, not currently known to be pregnant  or breas tfeeding  288 
8. If female and sexually active, must agree to use a form of contraception to prevent pregnancy 289 
while a participant in the study.  A negative serum or urine pregnancy test will be re quired 290 
for all females of child bearing potential. Participants who become pregnant will be 291 
discontinued from the study. Also, participants who during the study develop and express 292 
the intention to become pregnant within the timespan of the study will be discontinued.  293 
9. Willingness to suspend use of any personal CGM for the duration of the clinical trial once the 294 
study CGM is in use  295 
10. Willingness to use the UVa artificial pancreas system throughout study sessions. 296 
11. Willingness to switch to lispro (Humalog) or aspart (Novolog) if not using already, and to use 297 
no other insulin besides lispro (Humalog) or as part (Novolog) during the study  298 
12. Total daily insulin dose (TDD) at least 10 U/day  and not more than 100 U/d 299 
13. Willingness not to start any new non- insulin glucose -lowering agent during the course of the 300 
trial (including metformin, GLP -1 agonists, pramlintide, DPP -4 inhibitors, biguanides, 301 
sulfonylureas and naturaceuticals)  302 
14. Willingness to eat at least 1  g/kg  of carbohydrate per day during the hotel  (or rental house , 303 
in the case of the pilot ) admission  304 
15. Willingness to reschedule Study Dinner Sessions if placed on oral steroids  305 
16. An understanding and willingness to follow the protocol and signed informed consent  306 
17. Willingness to commit to self -quarantine for at least 5 days before COVID testing . The COVID 307 
testing  will occur 2 -3 days before the hotel study .  Also, a willingness to comply with COVID 308 
precautions as outlined in section 10.3. The COVID tes t must be negative.  309 
 
 310 
The participant must not have any exclusion criteria in order to be eligible to participate in the 311 
study.  312 
1. History of diabetic ketoacidosis (DKA) in the 12 months prior to enrollment  313 
2. Severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months prior to 314 
enrollment  315 
3. Pregnancy or intent to become pregnant during the trial  316 
4. Currently being treated for a seizure disorder  317 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 21 of 61 
 5. Planned surgery during study duration  318 
6. Treatment with any non- insulin g lucose -lowering agent (including metformin, GLP -1 agonists, 319 
pramlintide, DPP -4 inhibitors, SGLT -2 inhibitors, biguanides, sulfonylureas and 320 
naturaceuticals)   321 
7. A known medical condition that in the judgment of the investigator might interfere with the 322 
comple tion of the protocol . 323 
8. Use of an automated insulin delivery mechanism that is not downloadable by the subject or 324 
study team  325 
9. Known contact with a COVID -positive individual within 14 days of the hotel/rented house  326 
studies . 327 
10. A positive COVID Test within 14 days  of study participation, or during study participation.  328 
 
 329 
The participant will be evaluated for study inclusion and exclusion eligibility  after the informed 330 
consent form has been signed by the participant and the study team .  331 
Individuals who do not initially meet study eligibility requirements may be rescreened at a later 332 
date per investigator discretion.  333 
1. Dem ographics  334 
o Date o f birth 335 
o Gender  336 
o Race  337 
o Ethnicity  338 
2. Medical History  339 
o Duration of disease (number of years)  340 
o Current insulin pump model  341 
o History of CGM use  342 
o Current treatment  343 
i. Basal rates  344 
ii. Carbohydrate ratios  345 
iii. Insulin sensitivity factors  346 
iv. Target glucose  347 
v. Average daily insulin  348 
o History of diabetic ketoacidosis  349 
o History of severe hypoglycemia  350 
o History of seizures  351 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 22 of 61 
 o Loss of consciousness  352 
3. Surgical history  353 
4. Allergies  354 
5. Concomitant medications  355 
6. Physical Examination – A historical history and physical report within 52 weeks of 356 
screening appointments may be used  357 
o Weight  358 
o Height  359 
o Blood pressure  360 
o Temperature  361 
o Heart Rate  362 
7. Screening Labs  363 
o Hemoglobin A1c point of  care  364 
o Urine or serum pregnancy test for all women  of childbearing potential  365 
Screening procedures will last approximately 1 -2 hours. Screening can be performed via video 366 
conference.  Once all results of the screening evaluations are available, a decision will be made 367 
to determine the participant’s eligibility for the study or if one or more part of the screening will 368 
have to be repeated. If at the first screening or repeat screening an exclusionary condition is 369 
identified, the participant will be excluded from participation with follow up and referred to their 370 
primary care physician as needed. The study physician may elect to rescreen participants if their 371 
clinical situation changes. No tably, screening is for determining study eligibility.  Once 372 
participants are found to be eligible, they can begin their self -quarantine and COVID testing as 373 
outlined above.  374 
 
 375 
The Demographic Data Survey will be electronically adminis tered once eligibility has been met.   376 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 23 of 61 
 Chapter 4  Randomization   377 
Participants will receive the three different experimental meals in random order as described 378 
below.  379 
 
 380 
Pilot participants will not be randomized but will only undergo  both a norm al carbohydrate 381 
announcement and an experimental dinner with the Rocket AP with no -carbohydrate 382 
announcement. 383 
 
 384 
Once eligibility is met, the participant may continue to randomization following arrival to the first  385 
hotel visit. Screen ing failures and study dropout participants may be replaced. Randomization 386 
will determine the order of the Study Dinner  Sessions, with potential  order as shown in Table 1 . 387 
 Study Dinner Sessions #1 & 2  
 (Hotel days 2 and 3 ) Study Dinner Sessions #3 & 4  
 (Hotel days 5 and 6 ) 
1. Rocket AP Control -IQ 
 Study Dinner Session 
#1:   
Normal CHO 
announcement  Study Dinner Session 
#2:   
No announced CHO 
(insulin priming and 
automated AP 
correction boluses )  Study Dinner Session 
#3:   
Normal CHO announcement  Study Dinner Session #4:   
No announced CHO  
(automated AP correction boluses)   
2. Control -IQ Rocket AP 
 Study Dinner Session #1:   
Normal CHO announcement  Study Dinner Session #2:   
No announced CHO 
(automated AP 
correction boluses)  Study Dinner Session 
#3:   
Normal CHO 
announcement  Study Dinner Session 
#4:   
No announced CHO 
(insulin priming and 
automated AP 
correction boluses)  
Table 1: Randomization Table  388 
Randomization will occur via selection from the above list using permuted blocks in groups of 4, 389 
4 and 2 .    390 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 24 of 61 
 Chapter 5  Study Equipment Training  391 
Equipment training may begin at arrival to  hotel after UVa AP syste m has been pu t in place.   The 392 
purpose of this training is to introduce the study insulin pump and study CGM to the participant.  393 
The participant’s insulin parameters will be programmed into their study insulin pump by two 394 
research staff. Subjects will then switch to the study insulin pump. The participant’s personal 395 
pump and infusion site will be removed.  396 
The participant will have the insulin pump and sensor on them at all times. Study supplied phones 397 
will be used if DiAs is the system utilized and otherwis e upon participant request.  398 
 
 399 
A study CGM will be provided to all participants at the training session. The participants will be 400 
provided with CGM equipment and instructed to use the study CGM on a daily basis. If the 401 
participant has  prior use of the CGM, re-training will be specific to the individual.  The study team 402 
may elect to have less frequent CGM users watch the Dexcom online training videos 403 
(https://www.dexcom.com/training -videos)  to assist in the training session.  Study staff t raining 404 
may include review of study CGM in real -time to make management decisions and how to review 405 
the data after an upload for retrospective review. Study staff will specifically identify how alarms 406 
are set using the app and the frequency that these al arms will repeat.  407 
The participants personal CGM will be discontinued. The participants will be observed placing the 408 
sensor and will learn/review how to access the CGM trace via the DiAs phone or the Tandem 409 
research pump, as needed . The participants will be  asked to perform fingerstick blood glucose 410 
measurements (if needed) in accordance with the labeling of the study CGM device.  411 
An electronic copy of the CGM user’s guide will be provided for the participants to read . The 412 
study team will be sure that the pa rticipants will leave the training session  knowing how to use 413 
proper use the CGM. The study team will be available for any questions.  414 
Participants will have the option of using their personal smartphone or receive a study 415 
smartphone to use in order to collect the data from the devices.  If the participant elects to use a 416 
personal device, the Dexcom app will be downloaded to their phone in order to monitor the 417 
participant’s CGM values and alerts in real- time may be used.  418 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 25 of 61 
 
 
 419 
All participants may  be asked to wear an activity tracker (e.g. Fitbit) during the entire study (home 420 
and hotel admissions) to record i nformation about movement and heart rate though not an 421 
endpoint in this study.  422 
 
 423 
The study team will be responsible monitori ng and managing the study insulin pump during the 424 
hotel admission s. The participants may be provided a quick overview  on its functionality if they 425 
understand the equipment.  426 
 Study Insulin Pump Topics   427 
• The study team will assist the participant in study pump  infusion site initiation and will 428 
start the participant on the study pump. The study pump will be programmed with the 429 
participant’s usual basal rates and pump parameters. The participant’s personal pump 430 
will be removed.  431 
• The participant will be instructed infusion site initiation, cartridge/priming procedures, 432 
setting up the pump, charging the pump, navigation through menus, bolus procedures 433 
including stopping a bolus, etc.  434 
 Other Issues  435 
The participant will be instructed to  notify study staff if they exper ience any issues with the study 436 
devices during the hotel admission. Staff will be present in the event that if insulin is delivered 437 
by any means other than the study pump (e.g. injection of subcutaneous insulin via syringe in the 438 
event of infusion site fai lure). If insulin is delivered by any means other than the study pump, the 439 
study team  will be instructed to turn off closed -loop mode  for approximately four hours.  440 
The participant will be asked to alert  the study clinical staff during periods of illness that develops 441 
during use of the AP system ( elevated temperature >101.5 degrees Fahrenheit [ 38.6 degrees 442 
Celsius ], periods of significant illness, or during periods of use of medications such as epinephrine 443 
for the emergency treatment of a severe allergic rea ction or asthma attack in addition to use of 444 
oral or injectable glucocorticoids to determine if closed -loop use should be temporarily 445 
discontinued.  446 
The participant will also be asked to alert  the study clinical staff for technical issues with the 447 
Tandem re search pump and/or the DiAs system, including use of t he study pump and study CGM 448 
(open loop mode) during periods of component disconnections or technical difficulties.  Study 449 
staff contact information will be provided to the participant.  450 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 26 of 61 
 A glucagon emerg ency kit will be available. Participants who currently do not have one will be 451 
given a prescription for the glucagon emergency kit.  452 
Glycemic Treatment Guidelines will be available for staff use  during the study  admissions . 453 
 Optimization of Insulin Pump Settings  454 
Data -driven optimization of pump settings can occur any time during the study, particularly if the 455 
participant contacts the study physician due to concerns about their pump settings due to 456 
recurring hypo - or hyperglycemia.   457 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 27 of 61 
 Chapter 6   Pilot Study   458 
In order to optimize the flow of the study visits during the Main Study , we will perform a Pilot 459 
Study at a local hotel . The duration of the hotel admission will be up to 48 hours with the intent 460 
of collecting appropriate safety data that will be presented to the study Medical Monitor for 461 
review.  Pilot study participants are eligible to enroll in the Main Study.  462 
 
 463 
Participants  not familiar with the CGM  will wear the CGM  at home for approximately 14 days. 464 
Other participants  who  are familiar with the CGM  will immediately proceed to the hotel/rented 465 
house  admission. If currently using a Dexcom G6, up to 30 days of data may be obtained from 466 
the participant’s personal CGM.  467 
 
 468 
For the pilot study, t here will be at least two study staff present at all times at the study site, at 469 
least one of whom will be clinical staff (e.g. nurse, physician, nurse practitioner). There will be a 470 
physician available either on -site or off-site within a 20 -minute drive at all times.  All study st aff 471 
will have received COVID testing within 72 hours of the start of the pilot study.  In addition, one 472 
of the study medical physicians and one senior engineer will be on call during the entire 473 
admission. Glucagon for the emergency treatment of hypoglycemi a will be available on -site.  474 
 
 475 
Pilot participants will be contacted by the study team approximately 24-48 hours prior to the 476 
hotel admission to verify the following information:  477 
• Inquire about any changes to the participant’s medical history  478 
• Inquire about the participant’s self- quarantine , possible COVID exposures, and study - 479 
related initial COVID Testing. 480 
• Study equipment (e.g. CGM  and activity tracker) initiation has occurred  481 
• Determine pump profile(s) the participant uses on ce rtain days  482 
• New CGM sensor has been placed approximately 24- 72 hours prior to admission  for 483 
proper warm- up 484 
• Verify with the participant that the goal CGM reading at time of arrival is less than 2 00 485 
mg/dL; this may require contact with the study physician prior to arrival on the day of the 486 
study visit  487 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 28 of 61 
 • Should any concerns regarding medical history, pump information, or unforeseen issues 488 
arise, the admission will be cancelled for that participant at the discretion of the 489 
investigator  490 
 
 491 
For the pilot study, one p articipant  will be assessed at a time.  The participant  will arrive at  the 492 
hotel or rented house “bubble” on the first day of the admission.  The study team will perform 493 
vital signs and inquire about the participant’s self -quarantine , COVID Testing,  and any changes to 494 
the participant’s medical history.  Any changes to medical history will be communicated to the 495 
medical physician to ensure continued eligibility and participation.   496 
Participants will at this point have the second COVID Test administered.  497 
A urine pregnancy test will be collected. The test must be negative for the participant to continue 498 
with the study.  499 
The subject’s CGM reading and ketone concentration will be recorded. In the event that the 500 
participant’s CGM reading is not between 80 -250 mg/dL or ketone concentration is ≥ 0.6 mmol/L 501 
prior to initiation  of the UVa AP system , the study physician may recommend  additional insulin 502 
dosing according to the participants’ usual do ses. Study physician may elect to cancel 503 
participant’s participation in the hotel admission if concerned about their medical safety.  This 504 
participant will not be replaced.  505 
The participant’s home  insulin pump will be discontinued,  and the study Tandem res earch  insulin 506 
pump will be initiated.  The study team will ensure the proper function of the CGM, insulin pump, 507 
and activity tracker. The goal will be to initiate Closed Loop  Control by approximately 3-4 pm , 508 
running the RocketAP  system  and the DiAs platfor m.  509 
The CGM used in the study is FDA -approved for the non- adjunctive measurement of blood 510 
glucose (i.e. the CGM reading can be used for insulin dosing decisions). The CGM readings will be 511 
the primary source of blood glucose values .  There are no protocol fingerstick blood glucose 512 
measurements other than at times of CGM calibration (if necessary) and if directed by the study 513 
team.  514 
 
 515 
  The study physician will suggest appropriate treatment If CGM is <70 mg/dL or > 250 mg/dL, or 516 
ketone test is >0.6 mmol/L.  The study team may request fingersticks as needed. The study 517 
subject may continue participation in the trial once CGM is between 70 -250 mg /dL and ketone 518 
concentration is ≤0.6 mmol/L.  519 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 29 of 61 
 If CGM is >25 0 for more than 3 hours  or >400 mg/dL at any time, study physician will be notified,  520 
and ketones will be checked . If ketone concentration is >0.6 mmol/L, the study team will check 521 
the insulin pump infusion site and correction insulin will be administered per study physici an 522 
judgement via the subject’s insulin pump. The study team will monitor CGM changes and ketones 523 
will be checked every 60 minutes until ketone concentra tion is ≤0.6 mmol/L.   If ketone 524 
concentration is ≥3.0 mmol/L, the study physician will recommend the appropriate medical 525 
treatment.    526 
If CGM <60 mg/dL at any time, subjects will be given approximately 8 -16 grams of fast -acting 527 
rescue carbohydrates.  Study team will monitor CGM rise and will consider treating again if CGM 528 
<80 mg/dL after approximately 20 minutes . Hypoglycemic treatments can occur at any time per 529 
study physician request.  530 
 
 531 
Participants will eat a structured dinner at approximately 6 -7 pm  during the admission. The 532 
participant will not ann ounce carbohydrate ingestion, allowing testing of the Meal Control 533 
Module on the RocketAP . During the time outside of the Study Dinner Sessions will continue in  534 
closed loop mode until it is time for discharge .  535 
 
 536 
Participants will be free to engage in low -intensity activity ( i.e. walking , kicking soccer ball) during 537 
the admission . Participants will enjoy  quiet activities in the  evening.  538 
 
 539 
Discharge will be at approximately 8 a.m. If the CGM values are above 300 mg/dL and ketone 540 
values are >0.6 mmol/L, the study team will check the insulin pump infusion site and correction 541 
insulin will be administered per study physician judgement v ia the subject’s insulin pump.    542 
Participants will be asked to continue monitoring ketone levels for 24 -48 hours after the hotel 543 
admission  if ketones were present at time of discharge. Urine ketone supplies may be provided  544 
for this testing.  545 
 
 546 
Approximately 24-48 hours after the hotel admission , the study team will contact the participant 547 
via phone/email/text /text to assess adverse events, adverse device effects, and device issues  548 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 30 of 61 
 
 
 549 
At the conclusion of the Pilot Study, the medical monitor will review the data as referenced in 550 
Chapter 9 .   551 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 31 of 61 
 Chapter 7   Main Study  552 
Main Study participants will participate in two hotel admissions. Each admission  will be up to  90 553 
hours in duration . The two study admissions should be less than 8 weeks apart. The study 554 
physician will need to determine if second admission can be completed if greater than 8 weeks 555 
from the first admission.  556 
 
 557 
Participants who are not familiar with the Dexcom G6  CGM will wear the equipment at home for 558 
approximately 14 days  to ensure proper use of the equipment during the two hotel admissions. 559 
Other participants will immediately proceed to the hotel admissions.  560 
 
 561 
There will be at least three  study staff present at all times at the study site, at least one of whom 562 
will be clinical staff (e.g. nurse, physician, nurse practitioner). There will be a physician inside the 563 
“bubble” during the study  at all times.  In addition, at least  one senior engineer will be on call 564 
during the entire admission. Glucagon for the emergency treatment of hypoglycemia will be 565 
available on -site. 566 
 
 567 
Participants will be contacted by the study team approximately 24-48 hours prior to each  hotel 568 
admission  if most recent contact with than study participant exceeds 10 days. This is in addition 569 
to the COV ID testing for participants. The study team will verify the following information:  570 
• Inquire about any changes to the parti cipant’s medical history  571 
• Confirm participant has self- quarantined and study -related initial COVID testing.   572 
• Study equipment (e.g. CGM and activity tracker) initiation has occurred  573 
• Determine pump profile(s) the participant uses on certain days  574 
• New CGM senso r has been placed approximately 24- 72 hours prior to admission for 575 
proper warm- up 576 
• Verify with the subject that the goal CGM reading at time of arrival is less than 2 00 mg/dL; 577 
this may require contact with the study physician prior to arrival on the day of the study 578 
visit  579 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 32 of 61 
 • Should any concerns regarding medical history, pump information, or unforeseen issues 580 
arise, the admission will be cancelled for that participant at the discretion of the 581 
investigator  582 
 
 583 
Participants will arrive at the hote l “bubble” on the first day of the admission.  As described in 584 
section 10.3, all participants will receive a second test for COVID -19 after arriving  for the stduy .  585 
The study personnel will wear N95 masks and goggles when less than 6 feet from participants 586 
until this COV ID test returns negative.  The study team will perform vital signs and inquire about 587 
any changes to the participant’s medical history.  Any changes to medical history will be 588 
communicated to the medical physician to ensure continued eligibility and participation.   589 
A urine pregnancy test will be collected. The test must be negative for the participant to continue 590 
with the study.  591 
The subject’s CGM readin g and ketone concentration will be recorded. In the event that the 592 
participant’s CGM reading is not between 80 -250 mg/dL or ketone concentration is ≥0.6 mmol/L 593 
prior to initiation of the UVa artificial pancreas system, the study physician may recommended 594 
additional insulin dosing according to the participants’ usual doses. Study physician may elect to 595 
cancel participant’s participation in the hotel admission if concerned about their medical safety.  596 
This participant will not be replaced.  597 
The participant’s home insulin pump will be discontinued,  and the study insulin pump will be 598 
initiated.  The study team will ensure the proper function of the CGM, insulin pump, and activity 599 
tracker.   600 
The CGM used in the study is FDA -approved for the non- adjunctive measurement of blood 601 
glucose (i.e. the CGM reading can be used for insulin dosing decisions). The CGM readings will be 602 
the primary source of blood glucose values.  There are no protocol fingerstick blood glucose 603 
measurements other than at times of CGM calibration (if necessary) and if directed by the study 604 
team.  Glycemic Treatment Guidelines to be used during the hotel admission are defined in 605 
Chapter 8 . 606 
 
 607 
The study physician will suggest appropriate treatment If CGM is <70 mg/dL or >250 mg/dL, or 608 
ketone test is >0.6 mmol/L.  The study team may request fingersticks as needed. The study 609 
subject may continue participation in the trial once CGM is between 70 -250 mg /dL and ketone 610 
concentration is ≤0.6 mmol/L.  611 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 33 of 61 
 If CGM is >250 for more than 3 hours or >400 mg/dL at any time, study physician will be notified 612 
and keton es will be checked.  If ketone concentration is >0.6 mmol/L, the study team will check 613 
the insulin pump infusion site and correction insulin will be administered per study physician 614 
judgement via the subject’s insulin pump.  The study team will monitor CGM changes and ketones 615 
will be checked every 60 minutes until ketone concentra tion is ≤0.6 mmol/L.   If ketone 616 
concentration is ≥3.0 mmol/L, the study physician will recommend the appropriate medical 617 
treatment.    618 
If CGM <60 mg/dL at any time, subjects will be given approximately 8 -16 grams of fast -acting 619 
rescue carbohydrates.  Study team will monitor CGM rise and will consider treating again if CGM 620 
<80 mg/dL after approximately 20 minutes.  Hypoglycemic treatments can occur at any time per 621 
study physician re quest.  622 
 
 623 
Study Dinner Sessions start approximately 3 -4 hours before the participant eats dinner and will 624 
continue for approximately 12 hours after the dinner. Participants will eat a structured dinner at 625 
approximately 6 -7 pm  during the a dmission . The order of the AP system tested (RocketAP  vs. 626 
Contr ol-IQ) is determined randomly. The order of carbohydrate (CHO) announcement will be the 627 
same in both cases  (Table 1).  628 
• Study Dinner Session #1  and #3 :  Normal CHO announcement  629 
• Study Dinner Session #2 and # 4:  No announced CHO (Meal Control Module)  630 
Blood glucose levels will be followed via continuous glucose monitor with the goal of maintaining  631 
a blood glucose range 70 -180 mg/dL during the 6 hours following start of the meal. The closed 632 
loop session run between 3pm – 6 am and will be discontinued prior to time of discharge .  633 
Breakfast and lunch will be announced into each system during the hotel a dmissions.  634 
 
 635 
Participants will be free to engage in low -intensity activity ( i.e. walking , kicking soccer ball) during 636 
the hotel admission . If COVID precaution milestones are met (all participants and on -site study 637 
personnel are found t o be COVID -negative on second study COVID test performed at entrance to 638 
the “bubble,” see Section 10.3 ), limited activities with safe distancing and mask use may occur as 639 
described in Section 10.3 . Participants will enjoy quiet activities in the evening.  640 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 34 of 61 
 
 
 641 
Discharge will be at approximately 8 a.m. If the CGM values are above 300 mg/dL and ketone 642 
values are >0.6 mmol/L, the study team will check the insulin pump infusion site and correction 643 
insulin will be administered per study physician judgement v ia the subject’s insulin pump.    644 
Participants will be asked to continue monitoring ketone levels for 24 -48 hours after the hotel 645 
admission  if ketones were present at time of discharge. Urine ketone supplies may be provided 646 
for this testing.  647 
 
 648 
Participants will complete questionnaire (s) at the completion of each admission. Questionnaires 649 
are described in section 9.2. 650 
 
 651 
Approximately 24-48 hours after the hotel admission, the study team will contact the participant 652 
via phone/email/ text to assess adverse events, adverse device effects, and device issues  Medical 653 
Monitor Review  654 
 
 655 
At the conclusion of the Pilot Study, the medical monitor will review the data as referenced in 656 
section 8.3.    657 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 35 of 61 
 Chapter 8   Medical Monitor Review  658 
 
 659 
The Medical Monitor  will be provided all adverse event data from the Pilot Study for review  prior 660 
to the main study .  The Medical Monitor  will review data related to individual stopping criteria 661 
as detailed in the study protocol.   662 
 
 663 
After review, the Medical Monitor  can recommend that the current study continue without 664 
modification, continue with specified modifications, discontinue one or more arms of the study, 665 
or halt or modify the study until more information is available . 666 
The Medical Monitor may recommend modifications to individual stopping rules if additional 667 
safety concerns arise during from their continuing reviews of the study data.    668 
The ho tel admission will not be repeated unless required by the Medical Monitor .   669 
 
 670 
A Medical Monitor will review compiled safety data at the conclusion of the trial. In addition, the 671 
Medical Monitor  will review all DKA and severe hypoglycemia irrespective of relatedness to study 672 
device use, and all serious events (including UADEs) related to study device use at the time of 673 
occurrence. The Medical Monitor  also will be informed of any ADEs not meeting criteria for a 674 
UAD E if the Study PI requests the Medical Monitor review.  The Medical Monitor  can request 675 
modifications to the study protocol or suspension or outright stoppage of the study if deemed 676 
necessary based on the totality of safety data available.   677 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 36 of 61 
 Chapter 9   Testing Proced ures  678 
 
 679 
 HbA1c  680 
• A blood sample will be obtained at screening to obtain a baseline hemoglobin A1c level. 681 
Blood test may be obtained within 2 weeks prior to enrollment may be used for eligibility 682 
purposes.  683 
• HbA1c level may be me asured by study team using the DCA2000, a comparable point of 684 
care device , at time of screening   685 
• Labs may be obtained at a local laboratory (e.g. LabCorp) convenient to the participant.  686 
 Pregnancy Test  687 
• A serum or urine pregnancy test will be required for women of childbearing  potential at 688 
in person visit and admission.   Test must be negative to participate in the study.  689 
 
 690 
The Demographic Data Survey will be asked at only the screening appointment and will reflect 691 
the status of the adolescent participant.  692 
Participants will be provided a short questionnaire asking them to rate their experience with the 693 
study equipment.   694 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 37 of 61 
 Chapter 10  Risks Associated with Clinical Trial  695 
 
 696 
Risks and Benefits are detailed below. Loss of confidentiality is a potential risk; however, data are 697 
handled to minimize this risk . Hypoglycemia, hyperglycemia and ketone formation are always a 698 
risk in participants with ty pe 1 diabetes and participants will be monitored for these symptoms.  699 
 Venipuncture Risks  700 
A hollow needle/plastic tube may  be placed in the arm for taking blood samples  (e.g. external 701 
HbA1c measurements for inclusion criteria). Blood draws can cause some common reactions like 702 
pain, bruising, or redness at the sampling site.  Less common reactions include bleeding from the 703 
sampling site, formation of a small blood clot or swelling of the vein and surrounding tissues, and 704 
fainting.  705 
 Fingerstick Risks  706 
About 1 dr op of blood will be removed by fingerstick for measuring blood sugars and sometimes 707 
HbA1c or other tests. This is a standard method used to obtain blood for routine hospital 708 
laboratory tests.  Pain is common at the time of lancing.  In about 1 in 10 cases,  a small amount 709 
of bleeding under the skin will produce a bruise . A small scar may persist for several weeks . The 710 
risk of local infection is less than 1 in 1000 . This should not be a significant contributor to risks in 711 
this study as finger sticks are part of the usual care for people with diabetes.  712 
 Subcutaneous Catheter Risks (CGM)  713 
Participants using the CGM will be at low risk for developing a local skin infection at the site of 714 
the sensor needle placement . If a catheter is left under the skin for more than 24 hours it is 715 
possible to get an infection where it goes into the skin, with swelling, redness and pain.  There 716 
may be bleeding where the catheter is put in and bleeding under the skin causes a bruise (1 in 10 717 
risk).  718 
Study staff should verbally alert the participant that on rare occasions, the CGM may break and 719 
leave a small portion of the sensor under the skin that may cause redness, swelling, or pain at 720 
the insertion site . The participant should be further instructed to notify the study coordinator 721 
immediately if this occurs.  722 
 Risks of Hypoglycemia  723 
As with any person having type 1 diabetes and using insulin, there is always a risk of having a low 724 
blood sugar (hypoglycemia) . The frequency of hypoglycemia should be no more and possibly less 725 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 38 of 61 
 than it would be as part of daily living . Symptoms of hypoglycemia can include sweating, 726 
jitteriness, and not feeling well.  Just as at home, there is the possibility of fainting or seizures 727 
(convulsions) and that for a few days the participant may not be as aware of symptoms of 728 
hypoglycemia.  A CGM functioning poorly and significantly over- reading glucose values could lead 729 
to inappropriate insulin delivery.  730 
 Risks of Hyperglycemia  731 
Hyperglycemia is likely because of the study design including unannounced carbohydrate 732 
ingestion.  Also, hyperglycemia and ketonemia could occur if insulin delivery is attenuated or 733 
suspended for an extended period or if the pump or infusion set is not working properly.  A CGM 734 
functioning poorly and significantly under -reading glucose values  could lead to inappropriate 735 
suspension of insulin delivery.  736 
 Risks of Device Reuse  737 
Participant will be informed that FDA or relevant national authorities have approved the insulin 738 
pump, CGM, glucometer and ketone meter for single use and that by using the m among multiple 739 
patients, bloodborne pathogens (i.e. Hepatitis B) may be spread through the use of multiple 740 
users.  741 
The study CGM system is labelled  for single use only. The sensor (the component of the system 742 
that enters the skin) will be single use only.  The transmitter and receiver may be reused during 743 
the study after cleaning the device using a hospital -approved cleaning procedure. The transmitter 744 
is attached to the sensor but does not enter the skin and the receiver, if used, is a handheld  745 
device.  746 
The study insulin pumps are labe lled for single -patient use. During the study, this device may be 747 
reused after cleaning adhering to a hospital -approved cleaning procedure. All infusion set 748 
equipment will be single patient use only (infusion set insertion kits, tubing, cartridges etc.) .   749 
The study blood glucose meter and blood ketone meter are labe lled for single -patient use. 750 
During  the study, these devices may be reused after cleaning adhering to a hospital -approved 751 
cleaning procedure.   752 
 Device Cleaning I nstructions  753 
CGM cleaning instructions are provided in the Dexcom G4 P latinum (Professional) Cleaning and 754 
Disinfection manual (current edition) and a similar approach will be applied for the G6 version 755 
used in this study. The transmitter should be cleaned w ith Clorox Healthcare® Bleach Germicidal 756 
Cleaner or any disinfectant product in a spray bottle containing a bleach solution of 6500 parts 757 
per million with the EPA registration number 56392 -7.  The transmitter will be submerged in this 758 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 39 of 61 
 solution and then pla ced on an absorbent wipe or clean surface.  Two sprays will be dispensed 759 
from the Clorox cleaner onto each side of the transmitter. A nylon brush will be used to scrub the 760 
transmitter on all sides for 30 seconds.  The transmitter will be placed in the Clor ox Cleaner 761 
solution for one minute. Transmitter is then rinsed under flowing tap water for ten seconds. The 762 
transmitter will then be disinfected using a disinfectant product with EPA registration number 763 
56392- 7 using similar procedures as the cleaning proc ess.   764 
Per the pump manufacturer, the insulin pump will be cleaned with a damp lint -free cloth. Use of 765 
household or industrial cleaners, solvents, bleach, scouring pads, chemicals, or sharp instruments 766 
are prohibited. The pump should never be submerged i n water. If needed, use only a very mild 767 
detergent, such as a bit of liquid soap with warm water. A soft towel will be used to dry the pump.  768 
The Accu -Chek Guide glucometer is cleaned and disinfected with two separate Super Sani -Cloths 769 
(EPA number 9480- 4). The entire surface will be cleaned, making sure the surface stays wet for 2 770 
minutes. This step is repeated with a clean cloth for disinfecting the device.  771 
The Precision Xtra User’s Guide suggests that healthcare professionals use 10% bleach, 70% 772 
alcohol or 10% ammonia to clean the device.  773 
Equipment that touches intact skin will be cleaned with ethyl or isopropyl alcohol (70 -90%), 774 
quaternary ammonium germicidal detergent (i.e. Cavicide, EPA number 46781) or household 775 
bleach. The contact time on the surface depends on the method used to clean the equipment. 776 
Cavicide requires three minutes on the surface of the equipment. Clorox Germicidal Bleach Wipes 777 
require two minutes on the equipment. The surface should remain wet (i.e. slightly damp) with 778 
the disinfectant to be considered effective though not wet enough to leave drops of liquid.  779 
In the event a manufacturer updates cleaning procedures for their device, the study team will 780 
adhere to the most current recommendations.  781 
There is the risk of blood sampling collection and contamination from sampling techniques. Hand 782 
washing with either soap & water or waterless hand sanitizer will be used prior to caring for the 783 
study subject. Gloves will be worn during blood sample collection and processing. Medical 784 
personne l will continue to practice hygiene for the subject’s protection (i.e. hand washing, 785 
changing gloves frequently, disposing needles properly). Gloves will be removed and hands 786 
washed  or sanitized prior to leaving and upon return to the subject’s room. Soile d linen will be 787 
changed to minimize the transfer of pathogenic organisms.  788 
 Hb1Ac Risk  789 
An NGSP Point of Care analyzer (i.e. DCA Vantage Analyzer) will be utilized at the research site to 790 
obtain the subject’s HbA1c level.  791 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 40 of 61 
 
 Other Risks  792 
Some participants may develop skin irritation or allergic reactions to the adhesives used to secure 793 
the CGM, or to secure the insulin infusion sets for the continuous subcutaneous insulin infusion.  794 
If these reactions occur, different adhesives or “under -taping” (such as with IV 3000, Tegaderm, 795 
etc.) will be tried, sites will be rotated frequently, and a mild topical steroid cream or other 796 
medication may be required.  797 
Whenever the skin is broken there is the possibility of an infection.  The CGM and pump infusion 798 
sites are inserted  under the skin.  It is possible that any part that is inserted under the skin may 799 
cause an infection.  These occur very infrequently, but, if an infection was to occur, oral and/or 800 
topical antibiotics can be used.  The risk of skin problems could be greater if you use a sensor for 801 
longer than it is supposed to be used.  Therefore, participants will be carefully instructed about 802 
proper use of the sensor.  803 
Data downloaded from the CGM, pump, glucometer, and ketone meter will be collected for the 804 
study as meas ures of diabetes self -management behaviors . Some people may  be uncomfortable 805 
with the researchers' having such detailed information about their daily diabetes habits.  806 
 Known Potential Benefits  807 
It is expected that this protocol will yield increased knowledg e about using an automated closed- 808 
loop system with anticipatory action to control glucose levels . The individual participant may not 809 
benefit from study participation.  810 
 Risk Assessment  811 
Based on the facts that (1) adults and adolescents with diabetes experience mild hypoglycemia 812 
and hyperglycemia frequently as a consequence of the disease and its management, (2) the study 813 
intervention involves periodic automated insulin dosing that may increase the likelihood of 814 
hypoglycemia, and periodic automated attenuation of insulin delivery that may increase the 815 
likelihood of hyperglycemia, (3) mitigations are in place, and have been tested in prior studies 816 
using the investigational device system in the home setting, that limit the likelihood of excessive 817 
insulin dosing or prolonged withdrawal of insulin, and (4) rapid reversal of hypoglycemia and 818 
hyperglycemia can be achieved, it is the assessment of the investigators that this protocol falls 819 
under DHHS 46.405 which is a minor increase over minimal risk. In addition, it is the belief of the 820 
investigators that this study also presents prospect of direct benefit to the participants and 821 
general benefit to others with diabetes.  822 
 823 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 41 of 61 
 
 
 824 
The study is being conducted in compliance with the policies described in the study policies 825 
document, with the ethical principles that have their origin in the Declaration of Helsinki, with 826 
the protocol described herein, and with the standards of Good Clinical Practice (GCP).  827 
Whenever possible, data will be directly collected in electronic case report forms, which will be 828 
considered the source data.  829 
The protocol is considered a significant risk device study, due to the fact that the closed loop 830 
system is experimental.  Therefore, an investigational device exemption (IDE) from the U.S. Food 831 
and Drug Administration (FDA) is required to conduct the study.  832 
 
 833 
To mitigate risk o f exposure to COVID 19,  we will attempt to create a COVID- free “bubble.”.   This 834 
plan involves renting an entire floor of a hotel for study purposes only and taking steps to only 835 
allow entrance to those who are reasonably likely to be COVID -free (participants and study 836 
personnel) and protecting a COVID -free space in which they can stay (Env ironment).  837 
Acknowledging that zero risk is not possible, we seek to take steps that in almost every case 838 
exceed the protection offered by the standard- of-care for clinical care and other research 839 
activities —and that very likely is safer than the usual act ivities of these adolescents, who in their 840 
current daily lives go to stores, participate in activities with friends, and in many cases attend 841 
school.  Because of the restrictions that we will require , and testing we will employ, the 842 
participants are likely  to be at lower risk for COVID transmission  (during the study)  than if they 843 
were pursuing their usual daily lives.  844 
        Participants and Study Personnel  845 
We will follow a combination of self -isolation and testing to increase our likelihood of having all 846 
COVID -free entrants into the “bubble.”    847 
 848 
Figure 2: COVID Precautionary Timeline  849 

CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 42 of 61 
 As shown in the Figure 2 : 850 
1. Participants  will agree to stay quarantine for at least five days before being tested. This 851 
ensures that participants  will be tested at least five days after their last possible exposure. 852 
“Quarantine” (or variations of this word) will be defined as: staying home with no close 853 
contact for m ore than 15 minutes, or contact only with an N95 or equivalent mask, with 854 
anyone who might have been exposed to COVID.  Participants must get a nasal swab PCR 855 
test, this may be done at UVA or in their community.  856 
2. All participants  will be ineligible if they h ave had known COVID exposure or symptoms 857 
within 14 days of study start.  858 
3. All participants, staff (research coordinators, technicians), nurses and physicians will be 859 
tested with a COVID PCR test 48 -72 hours before being admitted to the study hotel.  Those 860 
with positive tests will be excluded from the study.   Participants will continue to self - 861 
quarantine in the time between testing and being admitted to the hotel. (This self- 862 
quarantine and testing regimen is well beyond the standard- of-care for current clinic al 863 
care and most other research interactions, both of which involve repeated interactions 864 
with patients/participants who have neither self- isolated nor been tested for COVID.)    865 
4. Upon  admission to the hotel, all participants and staff will receive a second  COVID PCR 866 
test.  Following this test, all participants will stay quarantined in their hotel room without 867 
leaving until this second test returns negative.  Until the second COVID tests return 868 
negative, all study staff who have to come within 6 feet of participants will wear N95 869 
masks and goggles when doing so.  870 
5. Any participants with positive test will be discharged from the study.  Hotel rooms of 871 
these participants will not be used further. We will limit  any personal interaction between 872 
study personnel and these individuals.  Any interaction will be with N95 masks , hospital 873 
gown, gloves,  and goggles. S tudy personnel will immediately change (and not reuse these 874 
clothes) and shower.  875 
6. Participants  will only share a room with a sibling or housemate that they are currently 876 
living with; otherwise , they must be alone in a room.  877 
7. Study staff and physicians will stay in the “bubble” with the participants.  The study team  878 
includes 2 study coordinator, 1 technician, 2 study physicians.  Nurses will be assigned to 879 
shifts of up to 12 hours; there will be a minimum of 2 nurses on site at all times  (and thus 880 
a total of 6 study personnel total) .  We anticipate up to 20 study participants in the 881 
“bubble.”  As described above,  study staff that will be onsite will have COVID 19 negative 882 
test within 48-72 hours of the admission.  All study staff onsite will abide by UVa clinical 883 
protocols currently in place for healthcare workers which stands as the standard- of care 884 
for those invo lved in patient care .  This  protocol  includes use of the HOOS Health Check 885 
app and using masks at all times  when with any other individual (participants or other 886 
study personnel ). To minimize the number of staff members required to be present for 887 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 43 of 61 
 the study , monitoring  of study equipment will be performed remotely.   Remote and on - 888 
site staff will communicate via a dedicated study phone.   889 
8. Because of the precautions we have put in place, we do not anticipate that participants 890 
or study personnel will have COVID  during the study.  However, participants or study 891 
personnel who develop symptoms of COVID during the study will be discharged from the 892 
“bubble” and receive COVID testing.  In the case of study personnel, back -up team 893 
members who have received a negative C OVID test hotel admission  will replace the 894 
member who developed symptoms.  895 
  Environment  896 
We are working to reduce risk of COVID exposure both by decreasing coronavirus on surfaces 897 
and avoiding any contact with hotel personnel.  To do so, we will take the following 898 
precautions:  899 
1. We will reserve  the entire study floor of the hotel starting at least 24 hours before 900 
admission.  While the rooms will have already been cleaned with the  hotel’s  cleaning 901 
protocol, keeping the rooms empty for 24 hours further allows time for inactivation of 902 
any coronavirus.  (This goes beyond the standard- of-care for clinical care and other 903 
research activities, which repeatedly utilize spaces throughout the day such as exam 904 
rooms and elevators, with cleaning of some surfaces but without allowing for inactivation 905 
of potential coronavirus on other surfaces not cleaned.)  906 
2. We will further clean the surfaces of each hotel room with disinfectant wipes before 907 
participants are admitted.  908 
3. The lobby of the hotel  will be avoided , instead using the  back stairwell.  We will verify that 909 
there are no other users of the stairwell before using it.  910 
4. Hotel staff will be instructed to avoid entrance to the study floor during the entirety of 911 
the stay . Housekeeping activities  will be cancelled during the study .  The only exception 912 
is breakfast delivery, which will be delivered by hotel staff in bags, either via the back 913 
stairwell and left on the floor at the entrance to the stairs or on the elevator and left right 914 
in front of the elevator  (without having to ste p onto the study floor) .   915 
5. If hotel staff absolutely have to enter the floor for any purpose (e.g. plumbing failure), 916 
they will be requested to notify study personnel by phone before entering the study floor 917 
and will be asked to wear masks at all times  while on the floor .  If they need to enter a 918 
participant’s room, the participant will first leave to a safe room.  Following the hotel staff 919 
work, the participant’s room will receive a thorough wipe by study staff before the 920 
participant can return.  921 
6. Additional  food will be dropped off by study staff  (not in the hotel “bubble”) via the back 922 
stairwell, and left on the floor . 923 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 44 of 61 
 7. Food will then be delivered one room at a time to individual participants by on -site study 924 
staff.  Participants will eat their food in their  rooms.  925 
 Activities  926 
Group activities are important for this study, both for the physical activity (which is an 927 
important part of healthy diabetes control) and because of the otherwise completely 928 
confined space that constitutes the study.  Again, we seek to only pursue safe situations that 929 
meet or exceed what is currently allowed inside the UVa Health System for f aculty,  staff, 930 
students and visitors. (For example, Internal Medicine Grand Rounds is permitted inside, in - 931 
person, with spacing and mask use —but does not require the self -isolating and testing that 932 
we will e mploy) .   933 
1. There will be no group activities until all COVID tests performed at study entry have 934 
returned negative . Study personnel will wear 95 masks during this period.  935 
2. Group  activities will invol ve the following precautions:  936 
o Study personnel will be stationed at intervals within the group to supervise that 937 
participants remain separated by 6 feet at all times.  938 
o Use of masks will be required by study staff and participants at all times.  939 
Participants c aught without a mask during any part of the activity will be escorted 940 
back to the hotel and will not be able to participate  in subsequent activities.  941 
o We will always u se the back stairwell (not elevator, not lobby) to exit hotel.  942 
o We will utilize  a staggered  exit so that participants are always at least 6 feet 943 
separated from each other.   944 
o Walking will be the only form of t ransportation.  945 
o Preference for outdoor activities (e.g., walking, kicking soccer ball)  will always be 946 
sought . 947 
o We will avoid congested areas where distancing is not possible.    948 
o Any indoor activities will be only be in a UVa facility that has been wiped down 949 
before use and has adequate space to permit separation by at least 6 feet 950 
between individuals at all times. Study staff will be present to observe and verify 951 
that all participants keep masks on and keep distanced.  Entrance to the space 952 
will be via the shortest distance to the facility (e.g., direct entrance from outside 953 
or very short hallway that will only be used when there are no other ind ividuals 954 
in the hallway.  955 
All activities will abide by statewide restrictions on numbers of individuals 956 
together.  957 
o  958 
  959 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 45 of 61 
 Chapter 11    Adverse Events, Device Issues, and Stopping Rules 960 
 
 961 
 Adverse Events (AE)  962 
Any untoward medical occurrence in a study participant, irrespective of the relationship between 963 
the adverse event and the device(s) under investigation ( section 11.2 ) for reportable adverse 964 
events for this protocol).  965 
 Serious  Adverse Event (SAE)  966 
 Any untoward medical occurrence that:  967 
• Results in death.  968 
• Is life -threatening; (a non- life-threatening event which, had it been more severe, might 969 
have become life -threatening, is not necessarily considered a serious adverse event).  970 
• Requires inpatient hospitalization or prolongation of existing hospitalization.  971 
• Results in persistent or significant disability/incapacit y or substantial disruption of the 972 
ability to conduct normal life functions ( life threatening).  973 
• Is a congenital anomaly or birth defect.  974 
• Is considered a significant medical event by the investigator based on medical judgment 975 
(e.g., may jeopardize the participant or may require medical/surgical intervention to 976 
prevent one of the outcomes listed above).  977 
 Unanticipated Adverse Device Effect (UADE)  978 
Any serious adverse effect on health or safety or any life -threatening problem or death caused 979 
by, or associated with, a device, if that effect, problem, or death was not previously identified in 980 
nature, severity, or degree of incidence in the investigational plan or application (including a 981 
supplementary plan or application), or any other unanticipated serious problem  associated with 982 
a device that relates to the rights, safety, or welfare of participants (21 CFR 812.3(s)).  983 
 Adverse Device Effect (ADE)  984 
Any untoward medical occurrence in a study participant which the device may have caused or to 985 
which the device may have contributed. 986 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 46 of 61 
 
 Device Complaints and Malfunctions  987 
A device complication or complaint is something that happens to a device or related to device 988 
performance, whereas an adverse event happens to a participant. A device complaint may occur 989 
independently from an AE, or along with an AE . An AE may occur without a device complaint or 990 
there may be an AE related to a device complaint.  A device malfunction is any failure of a device 991 
to meet its performance specifications or otherwise perform as intended.  Performance  992 
specifications include all claims made in the labeling for the device.  The intended performance 993 
of a device refers to the intended use for which the device is labeled or marketed. (21 CFR 803.3).   994 
 
 995 
For this protocol, a reportable advers e event includes any untoward medical occurrence that 996 
meets one of the following criteria:  997 
• A serious adverse event  as defined in section 11.2 998 
• An Adverse Device Effect as defined in section 11.1.4, unless excluded from reporting in 999 
section 11.7  1000 
• An Adverse Event as defined in section 11.1.1  occurring in association with a study 1001 
procedure  1002 
• An AE as defined in section 11.1.1 which leads to discontinuation of a study device for 2 1003 
or more hours  1004 
• Hypoglycemia meeting the definition of severe hypoglycemia as defined in section 11.2.1  1005 
• Diabetic ketoacidosis (DKA) as defined in section 11.2.2 or in the absence of DKA, a 1006 
hypergly cemic or ketosis event meeting the criteria defined below  1007 
Hypoglycemia and hyperglycemia not meeting the criteria below will not be recorded as adverse 1008 
events unless associated with an Adverse Device Effect . Skin reactions from sensor placement 1009 
are only reportable if severe and/or required treatment.  1010 
 Hypoglycemia Event  1011 
Hypoglycemia not associated with an Adverse Device Effect is only reportable as an adverse event 1012 
when the following definition for severe hypoglycemia is met:   1013 
• the event required assistance of another person due to altered consciousness, and 1014 
required another person to actively administer carbohydrate, glucagon, or other 1015 
resuscitative actions  1016 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 47 of 61 
 • impaired cognitively to the point that he/she was unable to treat himself/herself, was 1017 
unable to verba lize his/ her needs, was incoherent, disoriented, and/or combative, or 1018 
experienced seizure or coma . These episodes may be associated with sufficient 1019 
neuroglycope nia to induce seizure or coma  1020 
• if plasma glucose measurements are not available during such an event, neurological 1021 
recovery attributable to the restoration of plasma glucose to normal is considered 1022 
sufficient evidence that the event was induced by a low plasma glucose concentration  1023 
 Hyperglycemia Events/Diabetes Ketoacidosis  1024 
Hyperglycemia not associated with an Adverse Device Effect is only reportable as an adverse 1025 
event when one of the following four  criteria is met:  1026 
• the event involved DKA, as defined by the Diabetes Control and Complications Trial 1027 
(DCCT) and described below  evaluation or treatment was obtained at a health care 1028 
provider facility for an acute event involving hyperglycemia or ketosis  1029 
• blood ketone level ≥1.5 mmol/L and communication occurred with a health care provider 1030 
at the time of the event  1031 
• blood ketone level  ≥3.0 mmol/L, even if there was no communication with a health care 1032 
provider  1033 
Hyperglycemic events are classified as DKA if the following are present:  1034 
• Symptoms such as polyuria, polydipsia, nausea, or vomiting  1035 
• blood ketones ≥1.5 mmol/L or large/moderate uri ne ketones  1036 
• Treatment provided in a health care facility  1037 
All reportable Adverse Events —whether volunteered by the participant, discovered by study 1038 
personnel during questioning, or detected through physical examination, laboratory test, or 1039 
other means —will b e reported on an adverse event form online.  Each adverse event form is 1040 
reviewed by the Medical Monitor to verify the coding and the reporting that is required.  1041 
 
 1042 
The study investigator will assess the relationship of any adverse event to be related or unrelated 1043 
by determining if there is a reasonable possibility that the adverse event may have been caused 1044 
by the study device.  1045 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 48 of 61 
 To ensure consistency of adverse event causality assessments, investigators should appl y the 1046 
following general guideline when determining whether an adverse event is related:  1047 
• There is a plausible temporal relationship between the onset of the adverse event and 1048 
the study intervention, and the adverse event cannot be readily explained by the 1049 
participant’s clinical state, intercurrent illness, or concomitant therapies; and/or the 1050 
adverse event follows a known pattern of response to the study intervention; and/or the 1051 
adverse event abates or resolves upon discontinuation of the study intervention or dose 1052 
reduction and, if applicable, reappears upon re -challenge.  1053 
• Evidence exists that the adverse event has an etiology other tha n the study intervention 1054 
(e.g., preexisting medical condition, underlying disease, intercurrent illness, or 1055 
concomitant medic ation); and/or the adverse event has no plausible temporal 1056 
relationship to study intervention.  1057 
 
 1058 
While we are taking significant steps to prevent transmission of COVID- 19 during this study, there 1059 
is a possibility that participants, based either on exposure before the hotel admission or during 1060 
the stay, are infected with COVID -19.  Infection with COVID- 19 could be determined by testing 1061 
48-hours prior to study admission (in which case would be deemed not related to the study), 1062 
testing at arrival to the hotel (again not related) or onset of new symptoms during the stay. The 1063 
probability that infection is related to the study may be inferred in part by the timing, with 1064 
symptoms beginning on day 1 or 2 of the study being more likely not related and onset of 1065 
symptoms afterward being possibly related to exposure during the study.  Any appearance of 1066 
COVID sympto ms in participants will be cause for repeat COVID testing an d quarantine  until test 1067 
results are returned.  I f the  positive, the participants will be discharged from the study . Study 1068 
team will use N95 masks, gown, gloves, and goggles until test results are  returned.  1069 
In the event of a COVID positive test in a participant , the study team will follow up with the 1070 
participant via phone until conclusion of treatment for the COVID related sy mptoms . All 1071 
participants will be asked to follow up via  phone with the study team in the event of a positive 1072 
test within 14 days after discharge from the hotel.  1073 
 
 1074 
The intensity of an adverse event will be rated on a three -point scale: (1) mild, (2) moderate, or 1075 
(3) severe . It is emphasized that the ter m severe is a measure of intensity: thus, a severe adverse 1076 
event is not necessarily serious . For example, itching for several days may be rated as severe, but 1077 
may not be clinically serious.  1078 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 49 of 61 
 • MILD: Usually transient, requires no special treatment, and does not interfere with the 1079 
participant’s daily activities.  1080 
• MODERATE: Usually causes a low level of inconvenience or concern to the participant and 1081 
may interfere with daily activities but  is usually ameliorated by simple therapeutic 1082 
measures.  1083 
• SEVERE: Interrupts a participant’s usual daily activities and generally requires systemic 1084 
drug therapy or other treatment.  1085 
 
 1086 
Adverse events will be coded per the UVA IRB website instructions (i.e. mild, moderate, severe).   1087 
The Medical Monitor  will review the investigator’s assessment of causality and may agree or 1088 
disagree.  Both the investigator’s and Medical Monitor ’s assessments will be recorded.  The 1089 
Medical Monitor will have the final say in determining the causality.  1090 
Adverse events that continue after the participant’s discontinuation or completion of the study 1091 
will be followed until their medical outcome is determined or until no further change in the 1092 
condition is expected.  1093 
 
 1094 
The outcome of each reportable adverse event will  be classified by the investigator as follows:  1095 
• RECOVERED/RESOLVED – The participant recovered from the AE/SAE without sequelae.  1096 
Record the AE/SAE stop date.  1097 
• RECOVERED/RESOLVED WITH SEQUELAE – The event persisted and had stabilized without 1098 
change in the event anticipated.  Record the AE/SAE stop date.  1099 
• FATAL – A fatal outcome is defined as the SAE that resulted in death. Only the event that 1100 
was the cause of death should be reported as fatal.  AEs/SAEs that were ongoing at the 1101 
time of death; however, were not  the cause of death, will be recorded as “resolved” at 1102 
the time of death.  1103 
• NOT RECOVERED/NOT RESOLVED (ONGOING) – An ongoing AE/SAE is defined as the 1104 
event was ongoing with an undetermined outcome.  1105 
• An ongoing outcome will require follow -up by the site in order to determine the final 1106 
outcome of the AE/SAE.  1107 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 50 of 61 
 • The outcome of an ongoing event at the time of death that was not the cause of death, 1108 
will be updated and recorded as “resolved” with the date of death recorded as the stop 1109 
date.  1110 
• UNKNOWN – An unknown outcom e is defined as an inability to access the participant or 1111 
the participant’s records to determine the outcome (for example, a participant that was 1112 
lost to follow -up). 1113 
All clinically significant abnormalities of clinical laboratory measurements or adverse ev ents 1114 
occurring during the study and continuing at study termination should be followed by the 1115 
participant’s physician and evaluated with additional tests (if necessary) until diagnosis of the 1116 
underlying cause, or resolution . Follow -up information should be  recorded on source documents.  1117 
If any reported adverse events are present when a participant completes the study, or if a 1118 
participant is withdrawn from the study due to an adverse event, the participant will be 1119 
contacted for re -evaluation within 2 weeks.  If the adverse event has not resolved, additional 1120 
follow -up will be performed as appropriate.  Every effort should be made by the Investigator or 1121 
delegate to contact the participant until the adverse event has resolved or stabilized.  1122 
 
 1123 
All UADEs, ADEs, device complaints, and device malfunctions will be reported irrespective of 1124 
whether an adverse event occurred, except in the following circumstances.  1125 
The following device issues are anticipated and will not be reported but will reported  as an 1126 
Adverse Event if the criteria for AE reporting described above are met:  1127 
• Component disconnections  1128 
• CGM sensors lasting fewer than the number of days expected per CGM labeling  1129 
• CGM tape adherence issues  1130 
• Pump infusion set occlusion not leading to ketosis  1131 
• Battery lifespan deficiency due to inadequate charging or extensive wireless 1132 
communication  1133 
• Intermittent device component disconnections/communication failures not leading to 1134 
system replacement  1135 
• Device issues clearly addressed in the user guide manual that do not require additional 1136 
troubleshooting  1137 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 51 of 61 
 • Skin reactions from CGM sensor placement or pump infusion set placement that do not 1138 
meet criteria for AE reporting  1139 
 
 1140 
• UADEs must be reported within 10 working days to the FDA  after the sponso r first 1141 
receives notice of the adverse effect.  1142 
• Other reportable adverse events, device malfunctions (with or without an adverse event) 1143 
and device complaints should be reported promptly, but there is no formal required 1144 
reporting period.  1145 
• The IDE Sponsor will investigate the UADE and if indicated, report the results of the 1146 
investigation to the IRBs, FDA , and DSMB  within 10 working days of the study team  1147 
becoming aware of the UADE per 21CFR 812.46(b) (2).  1148 
• The Medical Monitor will determine if the UADE presents  an unreasonable risk to 1149 
participants. If so, the DSMB  must ensure that all investigations, or parts of investigations 1150 
presenting that risk, are terminated as soon as possible but no later than 5 working  days 1151 
after the  Medical Monitor makes this determinat ion and no later than 15 working  days 1152 
after first receipt notice of the UADE.  1153 
• In the case of a device system component malfunction (e.g. pump, CGM, control 1154 
algorithm), information will be forwarded to the responsible manufacturer by the study 1155 
personnel . 1156 
 
 1157 
 Participant Discontinuation  1158 
Rules for discontinuing study device use are described below.  1159 
• The investigator believes it is unsafe for the participant to continue on the intervention.  1160 
This could be due to the development of a new medical condition or worsening of an 1161 
existing condition; or participant behavior contrary to the indications for use of the device 1162 
that imposes on the participant’s safety  1163 
• The participant requests that the treatment be stopped  1164 
• The participant tests positive for COV ID-19 on either of the two scheduled COVID -19 tests 1165 
or subsequently develops symptoms for COVID- 19 and tests positive.  1166 
• Two distinct episodes of DKA , or one distinct episode of DKA attributable to study device 1167 
use. 1168 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 52 of 61 
 • Two distinct severe hypoglycemia events wi th BG <50 mg/dL and meeting the definition 1169 
in section 11.2.1  of the protocol, or one distinct severe hypoglycemia event attributable 1170 
to study device use, with BG <50mg/dL and meeting the definition in section 11.2.1 of the 1171 
protocol.  1172 
 Suspending/Stopping Overall Study  1173 
In the case of an unanticipated system malfunction resulting in a severe hypoglycemia or severe 1174 
hyperglycemia event (as defined in section 11.2.2), use of the study device system will be 1175 
suspended while the problem is diagnosed.  1176 
In addition, study activities could be similarly suspended if the manufacturer of any constituent 1177 
study device requires stoppage of device use for safety reasons (e.g. product recall).  The affected 1178 
study activities may resume if the underlying problem can be corrected by a protocol or system 1179 
modification that will not invalidate the results obtained prior to suspension. The study Medical 1180 
Monitor will review all adverse events and adverse device events that are reported during the 1181 
study and will review compiled safety data at periodic intervals (generally timed to the review of 1182 
compiled safety data by the Medical Monitor ). The Medical Monitor  may request suspension of 1183 
study activities or stoppage of the study if deemed necessary based on the totality of safety data 1184 
available.  1185 
 
 1186 
A Medical Monitor will review all DKA and severe hypoglycemia irrespective of relatedness to 1187 
study device use, and all serious even ts (including UADEs) related to study device use at the time 1188 
of occurrence. The Medical Monitor can request modifications to the study protocol or 1189 
suspension or outright stoppage of the study if deemed necessary based on the totality of safety 1190 
data available. Details regarding Medical Monitor  review will be documented in a separate 1191 
Medical Monitor document.    1192 
 
 1193 
A data breach is defined in the HITECH Act (43 USC 17932) as an unauthorized acquisition, access, 1194 
or use of protected health information (PHI) that compromises the security or privacy of such 1195 
information.   1196 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 53 of 61 
 Chapter 12  Miscellaneous Considerations  1197 
 
 1198 
Participants using glulisine at the time of enrollment will be asked to contact their personal 1199 
physician to change their prescribed personal insulin to lispro or aspart for the duration of the 1200 
trial.  1201 
The study devices (study  insulin pump, study CGM) must be removed before Magnetic Resonance 1202 
Imaging (MRI), Computed Tomography (CT) or diathermy treatment. Participants may continue 1203 
in the trial after temporarily discontinuing use if requiring one of the treatments above.  1204 
 
 1205 
Participation in the study is voluntary. Participant may withdraw at any time.  For  participants 1206 
who do withdraw  from the study , the study team will determine if their data will be used in 1207 
analysis.  1208 
 
 1209 
For security and confide ntiality purposes, subjects will be assigned an identifier that will be used 1210 
instead of their name.  Protected health information gathered for this study may be shared with 1211 
the third -party collaborators.  De -identified subject information may also be provided to 1212 
collaborators involved in the study after the appropriate research agreement has been executed.   1213 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 54 of 61 
 Chapter 13  Statistical Consideration  1214 
 
 1215 
The  main  study is itself a pilot study to assess glycemic responses to four  different approaches 1216 
to insulin dosing for carbohydrate ingestion , with two different AP systems ( Rocket AP and 1217 
Control -IQ, in random order ) each in sessions involving normal carbohydrate announcement and 1218 
no carbohydrate announcement (on successive nights) .  This information is de tailed in Table 1.  1219 
Randomization will occur via selection from the above list using permuted blocks in groups of 4, 1220 
4 and 2.    1221 
 
 1222 
As a Pilot Study , the goal will be complet e up to 20  participants  in the main study  to provide data 1223 
from a variety of individuals.  This number was chosen out of feasibility and not from a formal 1224 
power calculation.   (The pilot study for this proposal will assess ease of system use in up to 3 1225 
individuals prior to the beginni ng of the main study.)  1226 
 
 1227 
 Primary Efficacy Endpoint  1228 
The study design allows for multiple comparisons of blood glucose control during the Study 1229 
Dinner Sessions, with for the primary comparison of interest being between the no carbohydrate 1230 
announcement on the RocketAP  (running the Meal Probability Detector and the Meal Control 1231 
Module  algorithms) compared to no carbohydrate announcement on the Control -IQ system.  Our 1232 
primary endpoint is time -in-range 70 -180 mg/dL for the 6 -hour period after dinn er. Additional 1233 
comparisons are made between the Rocket AP system without vs. with normal carbohydrate 1234 
announcement (which determines efficacy vs. premeal bolus), as well as the Control -IQ system 1235 
without vs. with carbohydrate announcement (which determines risk of missed carbohydrate 1236 
announcement in standard of care system).  1237 
 Secondary Outcome s 1238 
For study period beginning after dinner and for 6h thereafter : 1239 
• Number of hypoglycemia events  1240 
• Time <70 mg/dL  1241 
• Time >180 mg/dL  1242 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 55 of 61 
 • Time >250 mg/dL  1243 
• Units of insulin injected  1244 
• Area under the curve when accounting for starting BG  1245 
For study period beginning of dinner until 12 hours later:  1246 
• Time in range 70 -180 mg/dL  1247 
• Number of hypoglycemia events  1248 
• Time <70 mg/dL  1249 
• Time >180 mg/dL  1250 
• Time >250 mg/dL  1251 
• Units of insulin injected  1252 
• Area under the curve when accounting for starting BG  1253 
We will also assess both safety and efficacy of the Rocket AP in adolescents by assessing outcomes 1254 
outside of the Study Dinner Sessions : 1255 
• Time in range 70 -180 mg/dL  1256 
• Number of hypoglycemia events  1257 
• Time <70 mg/dL  1258 
• Time  >180 mg/dL  1259 
• Time >250 mg/dL  1260 
• Units of insulin injected  1261 
 
 1262 
We will assess for the system’s functionality, including the ability of the system to run its code 1263 
without error (delivering insulin safely, as planned), as well as its ability to avoid low BG <70 1264 
mg/dL.  1265 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 56 of 61 
 
 
 1266 
Baseline demographic and clinical characteristics of the cohort of all randomized participants will 1267 
be summarized in a table using summary statistics appropriate to the distribution of each 1268 
variable. Desc riptive statistics will be displayed overall and by treatment group.  1269 
Will include:  1270 
• Age 1271 
• HbA1c 1272 
• Gender  1273 
• Race/ethnicity  1274 
• CGM use before enrollment  1275 
• Diabetes duration  1276 
• BMI 1277 
 
 1278 
The following tabulations and analyses will be performed during time on the UVa AP systems to 1279 
assess device issues:  1280 
• Device malfunctions requiring study team contact and other reported device issues  1281 
• Sensor performance metrics (difference, absolute relative difference, and International 1282 
Organization for Standardization criteria) – if applicable, by sensor version.  1283 
• % time CGM data available - overall and by month  1284 
• Performance metrics, describing the Closed Loop Control ( CLC) system and its 1285 
components like:  1286 
a. % time CGM data were available to the CLC system – overall and by month  1287 
b. % time in different operational modes per week - overall and by month  1288 
c. Rate of different failure events and alarms per 48  hours recorded by the CLC 1289 
system – overall and by month  1290 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 57 of 61 
 Data will not be used on any night where there is a site failure for the insulin pump and/or 1291 
malfunction of the CGM significantly effecting BG readings.   1292 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 58 of 61 
 Chapter 14   Data Collection and Monitoring  1293 
 
 1294 
The study data are collected through a combination of case report forms (electronic and paper) 1295 
and electronic device data files obtained from the software and individual hardware 1296 
components . These electronic device files and electronic CRFs are considered the primary source 1297 
documentation.  1298 
When data are directly collected in electronic case report forms, this will be considere d the 1299 
source data.  Records will be maintained in accordance with ICH E6 and institutional regulatory 1300 
requirements for the protection of confidentiality of participants.  1301 
 
 1302 
Study documents should be retained for a minimum of 2 years after the last approval of a 1303 
marketing application in an ICH region and until there are no pending or contemplated marketing 1304 
applications in an ICH region or until at least 2 years have elapsed since the formal 1305 
discontinuation of clinical development of the investigational product.  These documents should 1306 
be retained for a longer period, however, if required by local regulations . No records will be 1307 
destroyed without the written consent of the sponsor, if applicable . It is the responsibility of the 1308 
sponsor to inform the investigator when these documents no longer need to be retained.  1309 
 
 1310 
A protocol deviation is any noncompliance with the clinical trial protocol, Good Clinical Practices 1311 
(GCP), or procedure requirements.  The noncompliance may be either on the part of the 1312 
participant, the investigator, or the study site staff. As a result of deviations, corrective actions 1313 
may be developed by the site and implemented as appropriate.  Major deviations will be reported 1314 
to the IRB -HSR within 7 calendar days of when the study team becomes aware of the event.  1315 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 59 of 61 
 Chapter 15   Ethics/Protection of Human Participants  1316 
 
 1317 
The investigator will ensure that this study is conducted in full conformity with Regulations for 1318 
the Protection of Hum an Participants of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 1319 
CFR Part 56, and/or the ICH E6.  1320 
 
 1321 
The protocol, informed consent form(s), recruitment materials, and all participant materials will 1322 
be submitted to the IRB  for review and approval.  Approval of both the protocol and the consent 1323 
form must be obtained before any participant is enrolled.  Any amendment to the protocol will 1324 
require review and approval by the IRB before the changes are implemented to the study.  All 1325 
changes to the consent form will be IRB approved; a determination will be made regarding 1326 
whether previously consented participants need to be re -consented.  1327 
 
 1328 
 Consent Procedures and Documentation  1329 
Informed consent is a process that  is initiated prior to an individual’s agreement to participate in 1330 
the study and continues throughout the individual’s study participation.  Extensive discussion of 1331 
risks and possible benefits of participation will be provided.  Consent forms will be IRB a pproved 1332 
and the participant will be asked to read and review the document.  The investigator or their 1333 
delegate will explain the research study to the participant  and answer any questions that may 1334 
arise.  All participants will receive a verbal explanation i n terms suited to their comprehension of 1335 
the purposes, procedures, and potential risks of the study and of their rights as research 1336 
participants.  P articipant  will have the opportunity to carefully review the written consent form 1337 
and ask questions prior to  signing.  1338 
The participant and the parent(s)/ legal guardians will sign the informed consent document prior 1339 
to any procedures being done specifically for the study. The consent forms may be signed 1340 
electronically with the use of the HIPAA compliant version of  DocuSign. A copy of the informed 1341 
consent document will be given to the participant for their records.  The rights and welfare of the 1342 
participants will be protected by emphasizing to them that the quality of their medical care will 1343 
not be adversely affecte d if they decline to participate in this study.  1344 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 60 of 61 
 
 Participant and Data Confidentiality  1345 
The study monitor, representatives of the IRB or device company supplying study product may 1346 
inspect all documents and records required to be maintained by the investigator , including but 1347 
not limited to, medical records (office, clinic, or hospital) for the participants in this study.   1348 
The study participant’s contact information will be securely stored at the clinical site for internal 1349 
use during the study.  At the end of the study, all records will continue to be kept in a secure 1350 
location for as long a period as dictated by local IRB and Institutional regulations.  1351 
Study participant research data, which is for purposes of statistical analysis and scientific 1352 
reporting, will b e transmitted to and stored at the University of Virginia Center for Diabetes 1353 
Technology.  The study data entry and study management systems used by research staff will be 1354 
secured and password protected.  At the end of the study, all study databases may be  de- 1355 
identified and archived at the University of Virginia Center for Diabetes Technology.   1356 
CLINICAL PROTOCOL  
 
 
RocketAP _17-Nov-2020   Page 61 of 61 
 Chapter 16  References  1357 
1. Burdick J, Chase HP, Slover RH, et al. Missed insulin meal boluses and elevated 1358 
hemoglobin A(1c) levels in children receiving insulin pump therapy. Pediatrics. 1359 
2004;113(3):E221 -E224.  1360 
2. Olinder AL, Kernell A, Smide B. Missed bolus doses: devastating for metabolic control in 1361 
CSII-treated adolescents with type 1 diabetes. Pediatric Diabetes. 2009;10(2):142- 148.  1362 
3. Brown SA. The International Diabetes Closed -Loop iDCL) Trial-- Clinical Acceptance of the 1363 
Artificial Pancreas. The American Diabetes Association Scientifi c Sessions, San Francisco, 1364 
CA. 2019.  1365 
4. Cherñavvsky DR, DeBoer MD, Keith- Hynes P, et al. Use of an artificial pancreas among 1366 
adolescents for a missed snack bolus and an underestimated meal bolus. Pediatr 1367 
Diabetes. 2016;17(1):28- 35. 1368 